Article
Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir.
Revista do Instituto de Medicina Tropical de Sao Paulo - 1 Jan 2018
Gomes Lenyta Oliveira, Teixeira Marina Rodrigues, Rosa Júnior André da, Feltrin Alberi Adolfo, Rodrigues João Paulo V, Vecchi Mariane D'Avila, Carneiro Jane Meire M, Noblat Lúcia de Araújo C B, Chachá Silvana Gama F, Martinelli Ana de Lourdes C, Pereira Leonardo Regis L, Silveira Marysabel Pinto T, Blatt Carine Raquel, Farias Mareni Rocha
Abstract excerpt
In 2012, the first-generation protease inhibitors telaprevir (TVR) and boceprevir (BOC) were introduced in the Brazilian health system for treatment of chronic hepatitis C, after their approval by the National Committee for Health Technology Incorporation (CONITEC). However, these medicines were discontinued in 2015. The short period of use in therapy and their high cost require a discussion about the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.